Lincoln Pharmaceuticals Limited

LINCOLNDeep value region

A 6-pillar fundamental profile. Each pillar scored 0–10.

7.0/10 composite
Prism for LINCOLN.NS: composite 7.0 of 10, verdict Deep value regionPULSEQUALITYMOATSAFETYGROWTHVALUEBelow cohort range—7.28.09.07.4Below cohort range—

Pulse

— · Neutral

Pulse data unavailable; neutral placeholder

Pulse tracks recent momentum in price, analyst revisions, and news sentiment. Higher means more positive near-term tailwinds.

Quality

7.2 · Moderate

Piotroski 8/9, ROCE 16.1%

Quality captures profitability, return on capital, and earnings consistency. Higher means a better business.

Moat

8.0 · Strong

Wide moat

Moat estimates durable competitive advantages — brand, scale, switching costs. Higher means more defensible.

Safety

9.0 · Strong

D/E 0.00, Int cov 111.1x

Safety looks at balance-sheet quality, leverage, and cash generation. Higher means lower financial risk.

Growth

7.4 · Moderate

Rev CAGR 9.9%, EPS CAGR 17.1%

Growth reflects revenue and earnings expansion over recent years. Higher means faster compounding.

Value

— · Insufficient peer data

Only 0 MoS peers in cohort

Value measures how the stock's price compares to its intrinsic worth. Higher means more discount to fair value.

Compare with another stock

Overlay LINCOLN's prism against a peer.

Share this prism

Share on XWhatsApp

Get the full analysis

Interactive DCF, sensitivity, peer comparison, and AI summary for LINCOLN.

Full analysis →

Model estimate. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.